Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 9/20 | 0.39 |
| ▸ | CA2 | P00918 | 9/20 | 0.39 |
| ▸ | CA9 | Q16790 | 9/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807369 | 0.83 | CSNK1D (0.46) | NR1H4CA1CA2CA9PTGS2 | |
| SCHEMBL5026993 | 0.83 | PTGS2 (0.51) | NR1H4CA1CA2CA9PTGS2 | |
| SCHEMBL1779503 | 0.83 | PTGS2 (0.52) | NR1H4CA1CA2CA9PTGS2 | |
| SCHEMBL20805341 | 0.82 | NR1H4 (0.44) | NR1H4CA1CA2CA9PTGS2 | |
| SCHEMBL22722186 | 0.77 | NR1H4 (0.40) | NR1H4CA1CA2CA9PTGS2 | |
| SCHEMBL6163522 | 0.73 | KCNH2 (0.40) | NR1H4CA1CA2CA9PTGS2 | |
| SCHEMBL21792131 | 0.72 | — | — | |
| SCHEMBL2764186 | 0.70 | FYN (0.40) | CA1CA2CA9 | |
| SCHEMBL5396378 | 0.69 | NR1H4 (0.41) | NR1H4CA1CA2CA9PTGS2 | |
| SCHEMBL13703227 | 0.69 | KDM5A (0.48) | NR1H4CA1CA2CA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112074507-B | Compounds as Antibiotics | 山东亨利医药科技有限责任公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11498909-B2 | Compound acting as antibiotics | KBP BIOSCIENCES CO., LTD. (CN) | 2022-11-15 | — | — | US | disclosed |
| US-20200392096-A1 | COMPOUND ACTING AS ANTIBIOTICS | KBP BIOSCIENCES CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| US-20200392096-A1 | COMPOUND ACTING AS ANTIBIOTICS | KBP BIOSCIENCES CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| EP-3750881-A1 | COMPOUND ACTING AS ANTIBIOTICS | KBP Biosciences Co., Ltd. (CN) | 2020-12-16 | — | — | EP | disclosed |
| CN-112074507-A | Compounds as antibiotics | 山东亨利医药科技有限责任公司 | 2020-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498909-B2 | Compound acting as antibiotics | PEPD, NRDC, DPP4 | NR1H4 58/4885CA1 4040/4885CA2 2864/4885 |
| US-20200392096-A1 | COMPOUND ACTING AS ANTIBIOTICS | PEPD, NRDC, DPP4 | NR1H4 58/4885CA1 4040/4885CA2 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.